Postoperative recurrence of pancreatic cancer controlled for 9 months solely by severe carbohydrate restriction: ketogenic diet
Carbohydrate restriction (ketogenic diet) is a cancer treatment that reduces energy production by oxidative phosphorylation in mitochondria of cancer cells and increases it through anaerobic glycolysis in cytoplasm. We report a patient in whom progression of pancreatic cancer recurrence was suppressed solely by a ketogenic diet for 9-month post-surgery. A 60-year-old female with a diagnosis of pancreatic cancer underwent pancreatoduodenectomy after 3 cycles of chemotherapy with gemcitabine plus nab-paclitaxel. Multiple pulmonary metastases were observed 22 months after the surgery. We administered gemcitabine plus nab-paclitaxel for 1 year. As the partial response continued for 1 year, we performed radiotherapy for the remnant pulmonary metastases followed by administration of S-1 for 6 months. Ten months after radiotherapy, CT showed exacerbation of the pulmonary metastases. As treatment, she requested severe carbohydrate restriction. After 9 months of the ketogenic diet, CT revealed stable disease. A ketogenic diet may have the therapeutic effect of suppressing tumor progression if strictly applied.
Authors
- Naoto Yonamine
- Takahiro Einama
- Yasuhiro Takihata
- Masaki Hatakeyama
- Hideki Ueno (ORCID: https://orcid.org/0000-0002-8600-1199)
- Hanae Shinada
- Yoji Kishi (ORCID: https://orcid.org/0000-0001-8885-1210)
- Takazumi Tsunenari (ORCID: https://orcid.org/0000-0002-9852-6929)
- Sho Ogata (ORCID: https://orcid.org/0000-0002-2206-8482)
- Mikiya Takao (ORCID: https://orcid.org/0009-0003-2929-2086)
- Kazuki Kobayashi (ORCID: https://orcid.org/0000-0002-9365-9490)
Institutions
- Osaka Nishi Clinic (JP)
- National Defense Medical College (JP)
Publication Details
- Journal
- Clinical Journal of Gastroenterology
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1007/s12328-025-02221-z
- Primary Topic
- Diet and metabolism studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society of Clinical Oncology